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Abstract A variant of firefly luciferase in which the C-terminal 
end was extended with 44 amino acid residues served as a model 
protein in this study. After transcription and translation in vitro, 
the enzyme activity was measured when still attached to the 
ribosome and when released from the ribosome by incubation 
with RNase A or puromycin. It was found that the C-terminally 
extended luciferase already had activity when linked to the 
ribosome, but its activity was greatly increased when released 
from the ribosome. These results indicate that the luciferase is 
folded during synthesis on the ribosome; however, some 
conformational adjustments occur after its release from the 
ribosome which are required for the full expression of its 
enzymatic activity. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
How nascent peptide chains fold into their native confor-
mations is a basic problem in molecular biology. In 1988, 
Tsou proposed that peptide segments fold while being synthe-
sized but adjustments are necessary both during and after 
completion of the entire peptide chain [1]. In recent years, 
many reports have provided evidence that the nascent peptide 
begins to fold during its synthesis on the ribosome [2-7]. Lu-
ciferase from the Nor th American firefly Photinus pyralis cat-
alyzes the A T P and O z dependent oxidation of luciferin that 
results in a green light emission with a peak at 560 nm [8]. As 
luciferase does not require post-translational processing for 
enzyme activity, it has served as a model protein for studies 
of the folding of nascent peptide chains [6,7]. In 1994, Kolb et 
al. reported that the nascent luciferase peptide showed no 
activity when still linked to the ribosome, but activity was 
observed immediately upon its release from the ribosome, 
while a relatively long time was needed for refolding of the 
denatured mature luciferase in the same translation system. 
Therefore they concluded that luciferase begins to fold during 
its synthesis on the ribosome [6]. This conclusion is supported 
by the observation that the C-terminal 3CM-0 amino acid 
residues of the nascent peptide chain are shielded by the ri-
bosome [9,10] and that removal of the last 12 amino acid 
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residues from the C-terminus of firefly luciferase resulted in 
the loss of activity [11,12]. In 1996, Makeyev et al. showed 
that ribosome-associated luciferase acquired enzymatic activ-
ity when its C-terminus was extended by at least 26 additional 
amino acid residues [13]. In 1995, Kudlicki et al. also found 
that rhodanese extended with 23 amino acids was enzymati-
cally active while bound to the ribosome [14]. These results 
provide direct support for the hypothesis that proteins acquire 
tertiary structure as they are formed on the ribosome. 
In this study, a luciferase variant, which has the C-terminal 
end extended with 44 amino acid residues, is used as a model 
protein to investigate the folding of the protein while it is still 
linked to the ribosome and after it is released from the ribo-
some incubated with RNase A or puromycin. Our results 
show that the luciferase variant is enzymatically active while 
still bound to the ribosome but that a large increase in activity 
is observed after it is released from the ribosome, indicating 
that the protein has folded on the ribosome and that some 
conformational adjustments may occur upon release from the 
ribosome. 
2. Materials and methods 
2.1. Bacterial strains and plasmids 
Escherichia coli strain DH5a was used as a host cell in this study. 
pTZ18U, which contains multicloning sites and a T7 promoter, was 
from Bio-Rad. pGEM-luc, which has a BamHl-Sall restriction frag-
ment bearing the coding region for luciferase, was from Promega. 
pBVS-1 containing the coding sequence for staphylococcal nuclease 
R was constructed in this laboratory [15]. 
2.2. DNA manipulations 
Restriction endonucleases, as well as T4 DNA ligase were used as 
recommended by the manufacturer (Promega). Plasmid DNA isola-
tion and transformation of CaCl2-treated E. coli cells were carried out 
by the procedure of Sambrook et al. [16]. DNA sequencing was car-
ried out with the T7 DNA polymerase sequencing system under the 
conditions described by the manufacturer (Pharmacia). 
2.3. Construction of plasmids for expression of luciferase and 
C-terminally extended luciferase 
The plasmid used for expression of the wild-type luciferase in the 
cell-free translation system in vitro was constructed by isolating the 
BamHl-Sall restriction fragment using agarose gel electrophoresis 
after digestion of pGEM-luc with Bamiil and Sail. The fragment 
was then inserted into pTZ18U with the same restriction sites by 
ligation with T4 DNA ligase. The recombinant plasmid, named 
pTZ-LucI, contained the gene encoding the wild-type luciferase which 
could be expressed under the transcriptional control of the T^ pro-
moter in the presence of T7 RNA polymerase. 
The plasmid used for expression of the luciferase with C-terminal 
extension was constructed by amplifying an EcoRV-Kpnl fragment 
encoding the C-terminal amino acid residues of luciferase using a 
standard polymerase chain reaction (PCR) with Taq DNA polymer-
ase in which 5'-TACAAAGGATATCAGGTGG-3' (EcoRV site in 
the middle) and 5'-CTCGGTACCCAATTTGGACTTTCCGCC-3' 
(Kpnl tail with a CTC clamp at the 5' end) oligonucleotides were 
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used as upstream and downstream primers. The reaction substituted 
the stop codon TAA (UAA) of luciferase with a Kpnl recognition site 
GGTACC encoding glycine and threonine. A string of nucleotides 
encoding the C-terminal 42 amino acid residues of staphylococcal 
nuclease R was also amplified by PCR using 5'-CTCGGTACC-
GGCTTGTTGGCTAAAGTTGCT-3' (Kpnl tail with a CTC clamp 
at the 5' end) and 5'-GGGTCGACGTTAACCTGAATCAGCGT-
TGTC-3' (Sail tail with a GG clamp at the 5' end and a Hpal site 
in the middle containing the stop codon TAA) oligonucleotides as 
upstream and downstream primers. The two PCR products were 
then ligated with the larger EcoRN-Sall fragment of pTZ-lucI after 
digestion with EcoRVIKpnl and Kpnl/Sall. In this way, all of the 44 
additional amino acid residues were fused in frame with the C-termi-
nal end of luciferase. The recombinant plasmid thus obtained was 
named pTZ-LucII and the corresponding C-terminally extended luci-
ferase was named LucII (Fig. 1). 
2.4. In vitro transcription of the C-terminally extended luciferase gene 
The T7 transcription system (Promega) was used in this experiment. 
pTZ-LucII was first linearized with Hpal, which can cut off the 
stop codon TAA (UAA) of the luciferase LucII. The transcrip-
tion reaction was carried out in 100 ul of transcription mixture con-
taining 4 ug of linearized DNA template and 40 units of T7 RNA 
polymerase, incubated at 37°C for 2 h. After transcription, the tem-
plate DNA was removed by incubation with RNase-free DNase (1 U/ 
ug of linearized DNA template) at 37°C for 15 min. The reaction 
mixture was further extracted with phenol/chloroform and chloroform 
and precipitated by ethanol. An aliquot of mRNA solution was pu-
rified by G-50 spun-column chromatography to determine the concen-
tration of the mRNA [16]. An aqueous solution of mRNA (2 mg/ml) 
was used in the translation experiment. The purity of mRNA was 
examined using agarose gel electrophoresis according to the method 
of Liu [17]. 
2.5. In vitro translation of the C-terminally extended luciferase 
Cell-free translation was performed with wheat germ extract from 
Promega in 100 ul. The final concentration of mRNA was 100 ug/ml. 
The final K+ concentration was 120 mM and the final Mg2+ concen-
tration was 2.1 mM. Cold L-methionine in a final concentration of 80 
uM was used in the translation reaction when the products were 
assayed for luciferase activity. [35S]L-Methionine (1200 Ci/mmol) in 
a final concentration of 0.5 mCi/ml was used when the product was 
applied to SDS-PAGE. The translation reaction was carried out at 
25°C for 50 min. 
3. Results and discussion 
3.1. Construction of the pTZ-LucII containing the gene 
encoding the C-terminally extended luciferase 
The structure of the plasmid pTZ-LucII is shown in Fig. 1. 
The gene encoding the luciferase LucII (LucII) is under the 
transcriptional control of the T 7 promoter . There is no other 
A T G between the T 7 promoter and the LucII start codon. 
Therefore, in the presence of T 7 R N A polymerase, the LucII 
gene can be correctly transcribed in vitro. There is a unique 
Hpal site (GTTAAC) at the 3 ' end of this gene containing the 
stop codon T A A (UAA) which can be cut off by incubation 
with Hpal. The translation of m R N A produced from this 
/ /pal-linearized D N A resulted in ribosome-bound LucII. 
D N A sequencing analysis indicated that there are two mutant 
sites (V517G and K541M) in the sequence encoding the C-
terminal part of luciferase, but the luciferase activity assay 
indicated that these mutat ions do not damage the expression 
of the luciferase activity. 
3.2. Assay of products after transcription and translation in 
vitro 
The extended luciferase m R N A (minus stop codon UAA) 
was obtained by in vitro transcription as described in Section 
2.4. The m R N A is about 1800 nucleotides long and appears 
as a single band as judged from the 1.2% agarose gel electro-
phoresis pat tern which corresponds well to the LucII gene in 
size (data not shown). 
Fig. 2 shows the SDS-PAGE pattern of the proteins after 
translation. The pattern shows a major protein band with a 
molecular mass of 66 k D a (lane 1) in contrast to the control 
(lane 2), indicating that the LucII gene has been efficiently 
transcribed and translated. Some other protein bands of lower 
molecular mass also appear in lane 1, probably due to pre-
mature translation termination in the translation system. 
The translation products were fractionated as described in 
2.6. Sucrose gradient centrifugation 
A 100 ul aliquot of translation mixture was layered on top of linear 
20-45% sucrose gradients in buffer A (20 mM HEPES-KOH pH 7.5, 
2 mM Mg(CH3COO)2, 100 mM KCH3COO, 2 mM DTT). The mix-
ture was then centrifuged for 2.5 h at 35 000 rpm in an SW40 rotor at 
4°C. The gradients were collected from the bottom with approxi-
mately 500 ul for each fraction. The absorbency was then measured 
at 260 nm. 
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2.7. Assay of luciferase activity 
The luciferase assay system from Promega was used to assay the 
luciferase activity of each gradient fraction. 20 ul of the sample to be 
assayed was added to 100 ul of the assay buffer. Each reaction mix-
ture was immediately placed in a low level luminescence measurement 
instrument (model BPCL-4, made in China) with a 560 nm filter to 
record the time course of light emission. The luciferase activity was 
related to the light intensity integrated over 60 s. 
2.8. Release of nascent peptide from ribosome by incubation with 
RNase A or puromycin 
Two methods were used to release the nascent peptide from the 
ribosome. To use RNase A to release the nascent peptide from the 
ribosome, 80 ul of the ribosome fraction was incubated at 10°C with 
2 ul of RNase A (10 mg/ml) or distilled water (as control) for 30 min. 
To use puromycin to release the nascent peptide from the ribosome, 
40 ul of the ribosome fraction was incubated at 25°C with 4 ul of 
puromycin (20 mM) or distilled water (as control) for 30 min in the 
presence or absence of 2 ul of wheat germ extract or 2 ul of GTP (0.2 
mM). 
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Fig. 1. A: A schematic drawing of pTZ-LucII showing luciferase 
with C-terminal extension (LucII) under the transcriptional control 
of the T7 promoter. The EcoRN-Kpnl and Kpnl-Sall fragments are 
from the coding sequences of firefly luciferase and the C-terminal 
part of nuclease R, respectively. The 42 amino acid residues from 
the C-terminal end of nuclease were fused in frame with the C-ter-
minal end of luciferase through a linker peptide of Gly-Thr by 
PCR. There is no other ATG between this promoter and the start 
codon ATG of LucII. The gene can be correctly transcribed in vitro 
in the presence of T7 RNA polymerase. B: The partial sequence be-
tween the EcoRV and Sail sites. The stop codon TAA of luciferase 
was replaced with the Kpnl restriction site (GGTACC, encoding 
Gly and Thr). There is a unique Hpal site (GTTAAC) at the 3' end 
of LucII which contains the stop codon TAA. The stop codon can 
be removed from the LucII gene by digestion with Hpal. 
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Fig. 2. Fluorogram of SDS gel electrophoresis of the cell-free trans-
lation products. The translation products were applied to 15% poly-
acrylamide gel. The molecular mass in kDa is given on the left. 
Lane 1, the C-terminally extended luciferase translated from the 
mRNA transcribed from pTZ-LucII linearized with Hpal. Lane 2, 
the translation products without the added mRNA. 
Section 2.6. As shown in Fig. 3, two luciferase activity peaks 
were detected corresponding to the 80S ribosome fraction and 
the free protein fraction of the translation products. The ac-
tivity in the free protein fraction means that there are large 
amounts of full length luciferase being released from the ri-
bosome, although the stop codon is removed from the 
mRNA, as was observed previously [13]. 
3.3. Folding of the nascent luciferase is a cotranslational 
process 
As shown above, luciferase activity was detected in the 80S 
ribosome fraction, indicating that the luciferase LucII has al-
ready folded into an enzymatically active conformation while 
still linked to the ribosome. This result suggests that the fold-
ing of the nascent peptide of LucII is a cotranslational proc-
ess, which is consistent with Makeyev [13]. 
S a m p l e n u m b e r 
Fig. 4. Activity of luciferase LucII in the 80S ribosome fraction be-
fore and after treatment with RNase A. The ribosome fractions 
were treated with distilled water (1) or RNase A (2) or were not 
treated (3). The inset shows the original experimental data. 
3.4. Free luciferase may acquire a more favorable conformation 
for activity expression than ribosome-associated luciferase 
The luciferase activity in the 80S ribosome fractions before 
release from the ribosome was compared with the activity 
after release. As shown in Fig. 4, the luciferase activity in 
the ribosome fraction treated with RNase A (sample 2) is 
about 8.7 times that of the ribosome fraction without RNase 
A treatment (samples 1 and 3). Although some other possi-
bilities exist, the most reasonable explanation for the activity 
increase is that the luciferase molecule acquires a more favor-
able conformation state for expression of its activity after 
release from the ribosome due to changes in its microenviron-
ment, suggesting that some structural adjustment may be nec-
essary for the newly synthesized proteins to attain their final 
conformation, as was speculated previously [1,6]. 
Puromycin usually acts as an aminoacyl-tRNA analogue to 
release the nascent peptide from the ribosome [13,14]. In this 
experiment, puromycin was used to release LucII from the 
ribosome. As shown in Fig. 5, addition of puromycin (sample 
2) resulted in a slight activity increase for the ribosome-asso-
ciated LucII, but its efficiency was much lower than that of 
RNase A. Addition of both puromycin and wheat germ ex-
o 
Volume f r o m 
Fig. 3. Nascent luciferase activity in the 80S ribosome fraction of 
the wheat germ translation system. Cell-free translation products of 
luciferase LucII were fractionated as described in the text. The luci-
ferase activity in sucrose gradient fractions is shown by the unfilled 
columns. The absorbance at 260 nm is shown by the filled columns. 
1 2 3 4 
S a m p l e n u m b e r 
Fig. 5. Activity of luciferase LucII in the 80S ribosome fraction be-
fore and after treatment with puromycin. The ribosome fractions 
were treated with distilled water (1), puromycin (2) or puromycin 
and wheat germ extract (3) or were not treated (4). 
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tract (sample 3) resulted in a large activity increase, whereas 
puromycin mixed with G T P did not cause as large an activity 
increase (data not shown), indicating that some component 
other than G T P could promote the puromycin-induced release 
of the ribosome-associated LucII. 
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